The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside

Figure 2

A strategy map towards clinical grade iPSCs. Strict standards should be set to ensure the safety of cell replacement therapy using iPSC products. These standards for clinical grade iPSCs must cover but are not limited to generation of iPSCs with minimal mutation, assessment for tumorigenicity and immunogenicity, cell type and dosage selection, length of treatment window, and posttranslation monitoring, which requires the cooperation of lab researchers, clinicians, and business industry.